Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism

Thrombosis and Haemostasis

Volumn 93, Issue 3, 2005, Pages 592-599

  Aujesky, Drahomir ^a,b,c,d   Smith, Kenneth J ^a   Cornuz, Jacques ^b,c   Roberts, Mark S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Cost effectiveness; Treatment; Venous thromboembolism

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

AGED; ARTICLE; BLEEDING; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

COST-BENEFIT ANALYSIS; DECISION MAKING, COMPUTER-ASSISTED; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PREMEDICATION; QUALITY-ADJUSTED LIFE YEARS; THROMBOEMBOLISM; UNITED STATES; VENOUS THROMBOSIS; WARFARIN;

EID: 15344344484     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-11-0767     Document Type: Article

References (42)

1. Otten HM, Mathijssen J, Ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164: 190-4.
2. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
3. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-83.
4. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
5. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 58: 470-83.
6. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
7. Hull RD, Pineo GF, Mah AF, et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002; 100: 148a [Abstract].
8. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
9. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period. J Thromb Haemost 2003; 1 Suppl: OC194 [Abstract].
10. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
11. Levine M. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients. Semin Thromb Hemost 2003; 29 Suppl 1: 9-11.
12. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Pr, 1996.
13. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
14. Lee AY, Julian JA, Levine MN, et al. Impact of dalteparin low-molecular-weight heparin on survival: Results of a randomized trial in cancer patients with venous thromboembolism. Proc Am Soc Clin Oncol 2003; 22: 846 [Abstract].
15. Cook N, Thomas DM. Retrospective survey of unselected hospital patients with and without cancer comparing outcomes following venous thromboembolism. Intern Med J 2002; 32: 437-44.
16. Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982; 73: 889-97.
17. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001; 32: 2131-6.
18. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-5.
19. Meneveau N, Ming LP, Seronde MF, et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003; 24: 1447-54.
20. Kubba AK, Choudari C, Rajgopal C, et al. Reduced long-term survival following major peptic ulcer haemorrhage. Br J Surg 1997; 84: 265-8.
21. From the Medicare Provider Analysis and Review (MEDPAR) of Short-Stay Hospitals web site. Available at: http://cms.hhs.gov/statistics/medpar/default.asp. Accessed December 13, 2003.
22. White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med 1996; 156: 1197-201.
23. Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130: 789-99.
24. Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 2004; 116: 816-28.
25. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event: a decision and cost-effectiveness analysis. Am J Med (in press).
26. From the Centers for Medicare and Medicaid Services web site. Available at: http://cms.hhs.gov/providers/pufdownload/default.asp. Accessed December 13, 2003.
27. Drug Topics Red Book: Montvale, NY. Medical Economics, 2002.
28. From the U.S. Bureau of Labor Statistics web site. Available at: http://www.bls.gov/data/. Accessed December 13, 2003.
29. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459-66.
30. Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6: 59-74.
31. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5: 157-77.
32. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68-80.
33. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995; 332: 1418-24.
34. From the British National Formulary website. Available at: www.bnf.org. Accessed February 15, 2004.
35. From the French Formulary website. Available at: www.vidal.fr. Accessed February 16, 2004.
36. From the Swiss Drug Formulary. Available at: www.documed.ch. Accessed February 15, 2004.
37. From the Ontario Drug Benefit Formulary/Comparative Drug Index website. Available at: www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html. Accessed February 15, 2004.
38. Marchetti M, Pistorio A, Barone M, et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001; 111: 130-9.
39. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653-61.
40. Gold M, Franks P, Erickson P. Assessing the health of the nation. The predictive validity of a preference-based measure and self-rated health. Med Care 1996; 34: 163-77.
41. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997; 4: 49-56.
42. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839-45.